Financial results to be released after
market close; Conference call to be conducted at 5:00 pm ET
PHOENIX, Feb. 15,
2024 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES)
will report financial results for its fourth quarter and fiscal
year 2023, ended December 31, 2023,
after the market close on Wednesday,
February 21, 2024. The Company has scheduled a conference
call that same day, Wednesday, February 21,
2024, at 5:00 pm ET, to review
the results.
Fourth Quarter and Fiscal Year 2023 Conference Call
Details
Date and Time: Wednesday, February
21, 2024, at 5:00 pm ET
Call-in Information: Interested parties can access the
conference call by dialing (844) 308-3351 or (412) 317-5407.
Live Webcast Information: Interested parties can access
the conference call via a live webcast, which is available in the
Investor Relations section of the Company's website at
https://app.webinar.net/KODd6Vn6ApQ or
http://senestech.investorroom.com/.
Replay: A teleconference replay of the call will be
available for seven days at (877) 344-7529 or (412) 317-0088,
replay access code 3232725. A webcast replay will be available in
the Investor Relations section of the Company's website at
http://senestech.investorroom.com/ for 90 days.
About SenesTech
We are committed to improving
the health of the world by humanely managing animal pest
populations through fertility control. We are experts in fertility
control to manage animal pest populations. We invented
ContraPest, the only U.S. EPA-registered contraceptive for
male and female rats, and Evolve, an EPA-designated minimum-risk
contraceptive currently offered for rats. ContraPest
and Evolve fit seamlessly into all integrated pest management
programs, significantly improving the overall goal of effective
pest management. We strive for clean cities, efficient businesses
and happy households – with a product designed to be humane,
effective and sustainable.
For more information visit https://senestech.com/ and
https://contrapeststore.com.
Safe Harbor Statement
The foregoing paragraphs contain forward-looking statements that
involve estimates, assumptions, risks and uncertainties. Any
statements about our expectations, beliefs, plans, objectives,
assumptions or future events or performance are not historical
facts and may be forward-looking. "Forward-looking statements" may
be preceded by words such as "may," "future," "plan" or "planned,"
"will," "should," "expected," "anticipates," "continue,"
"eventually," "believes," or "projected." Forward-looking
statements include statements concerning the potential impact and
effects of the COVID-19 pandemic on the Company's business, results
of operations and financial performance; any measures the Company
has and may take in response to COVID-19 and any expectations the
Company may have with respect thereto; the Company's strategy and
target marketing and markets; continuing the Company's vision;
expected benefits of the Company's initiatives and continuation of
those initiatives; deployment of the Company's product; the
continuation or expansion of the use of ContraPest; demand for
ContraPest; the Company's expectation regarding costs, expenses and
cash and continuing its cost improvement plan; future financial
results; and the Company's execution of its strategic business
plan.
CONTACT:
Investor: Robert Blum, Lytham
Partners, LLC, 602-889-9700, senestech@lythampartners.com
Company: Tom Chesterman, Chief
Financial Officer, SenesTech, Inc., 928-779-4143
View original content to download
multimedia:https://www.prnewswire.com/news-releases/senestech-to-report-fourth-quarter-and-fiscal-year-2023-financial-results-on-wednesday-february-21-2024-302063367.html
SOURCE SenesTech, Inc.